Abstract
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance.
Funder
National Institutes of Health
Subject
Virology,Infectious Diseases
Reference87 articles.
1. World Health Organization, HIV/AIDS Fact Sheethttps://www.who.int/news-room/fact-sheets/detail/hiv-aids
2. Stages of HIV Replication and Targets for Therapeutic Intervention
3. World Health Organization, Update of Recommendations on First- and Second-Line Antiretroviral Regimenshttps://www.who.int/hiv/pub/arv/arv-update-2019-policy/en/
4. HIV-1 drug resistance and resistance testing
5. Human immunodeficiency virus reverse transcriptase and protease sequence database
Cited by
54 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献